Evidence map›Paper›PMID 33988700›Full record

ArticleBlood advances2021

Low-cost transcriptional diagnostic to accurately categorize lymphomas in low- and middle-income countries.

Fabiola Valvert, Oscar Silva, Elizabeth Solórzano-Ortiz, Maneka Puligandla, Marcos Mauricio Siliézar Tala, Timothy Guyon, Samuel L Dixon, Nelly López, Francisco López, César Camilo Carías Alvarado and 5 more

Abstract read
In one paragraph

Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Fabiola ValvertLa Liga Nacional Contra el Cáncer de Guatemala y El Instituto de Cancerología y Hospital Dr. Bernardo del Valle, Guatemala, Guatemala.ORCID 0000-0003-0687-2419
Oscar SilvaDepartment of Pathology, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0003-0808-2592
Elizabeth Solórzano-OrtizLa Liga Nacional Contra el Cáncer de Guatemala y El Instituto de Cancerología y Hospital Dr. Bernardo del Valle, Guatemala, Guatemala.
Maneka PuligandlaDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA.
Marcos Mauricio Siliézar TalaLa Liga Nacional Contra el Cáncer de Guatemala y El Instituto de Cancerología y Hospital Dr. Bernardo del Valle, Guatemala, Guatemala.
Timothy GuyonDxTerity Diagnostics, Rancho Dominguez, CA.
Samuel L DixonDxTerity Diagnostics, Rancho Dominguez, CA.
Nelly LópezLa Liga Nacional Contra el Cáncer de Guatemala y El Instituto de Cancerología y Hospital Dr. Bernardo del Valle, Guatemala, Guatemala.
Francisco LópezLa Liga Nacional Contra el Cáncer de Guatemala y El Instituto de Cancerología y Hospital Dr. Bernardo del Valle, Guatemala, Guatemala.ORCID 0000-0003-4038-4777
César Camilo Carías AlvaradoLa Liga Nacional Contra el Cáncer de Guatemala y El Instituto de Cancerología y Hospital Dr. Bernardo del Valle, Guatemala, Guatemala.ORCID 0000-0002-1515-0656
Robert TerbrueggenDxTerity Diagnostics, Rancho Dominguez, CA.
Kristen E StevensonDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA.
Yasodha NatkunamDepartment of Pathology, Stanford University School of Medicine, Stanford, CA.
David M WeinstockDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-8724-3907
Edward L BriercheckUniversity of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0003-0330-2752

Funding

Targeting High-Risk Lymphoid NeoplasmsR35CA231958 · NCI · DANA-FARBER CANCER INST · PI WEINSTOCK, DAVID MARC · 2019 to 2021
$2.9M
NCI NIH HHS R35 CA231958
6 · The paper itself

Abstract

Inadequate diagnostics compromise cancer care across lower- and middle-income countries (LMICs). We hypothesized that an inexpensive gene expression assay using paraffin-embedded biopsy specimens from LMICs could distinguish lymphoma subtypes without pathologist input. We reviewed all biopsy specimens obtained at the Instituto de Cancerología y Hospital Dr. Bernardo Del Valle in Guatemala City between 2006 and 2018 for suspicion of lymphoma. Diagnoses were established based on the World Health Organization classification and then binned into 9 categories: nonmalignant, aggressive B-cell, diffuse large B-cell, follicular, Hodgkin, mantle cell, marginal zone, natural killer/T-cell, or mature T-cell lymphoma. We established a chemical ligation probe-based assay (CLPA) that quantifies expression of 37 genes by capillary electrophoresis with reagent/consumable cost of approximately $10/sample. To assign bins based on gene expression, 13 models were evaluated as candidate base learners, and class probabilities from each model were then used as predictors in an extreme gradient boosting super learner. Cases with call probabilities < 60% were classified as indeterminate. Four (2%) of 194 biopsy specimens in storage <3 years experienced assay failure. Diagnostic samples were divided into 70% (n = 397) training and 30% (n = 163) validation cohorts. Overall accuracy for the validation cohort was 86% (95% confidence interval [CI]: 80%-91%). After excluding 28 (17%) indeterminate calls, accuracy increased to 94% (95% CI: 89%-97%). Concordance was 97% for a set of high-probability calls (n = 37) assayed by CLPA in both the United States and Guatemala. Accuracy for a cohort of relapsed/refractory biopsy specimens (n = 39) was 79% and 88%, respectively, after excluding indeterminate cases. Machine-learning analysis of gene expression accurately classifies paraffin-embedded lymphoma biopsy specimens and could transform diagnosis in LMICs.

Indexed as

Developing CountriesLymphoma, T-Cell, PeripheralBiopsyHumans

Identifiers

PMID33988700
PMCPMC8152509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.